



Louvain Drug Research Institute

Cellular and Molecular Pharmacology Unit

**UCL**

Université  
catholique  
de Louvain

# Interactions between Fluoroquinolones and lipids: Biophysical studies

Hayet BENSİKADDOUR

May 25<sup>th</sup>, 2011

Promoter Prof. Marie-Paule Mingeot-Leclercq

# Plan of the presentation

## I- Introduction

- ✓ Pharmacology of fluoroquinolones
- ✓ Mechanism of resistance of fluoroquinolones: efflux pumps phenomenon

## II- Aims of the Thesis

## III- Materials and Methods

## IV- Results

- ✓ Investigation of the interaction of two fluoroquinolones (**CIP** and **MXF**) with model lipid membranes

Bensikaddour et al., 2008: *Biophysical Journal* 94: 3035-3046

- ✓ Investigation of the interaction of **CIP** with eukaryotic and prokaryotic model lipids membranes (DPPC vs DPPG)

Bensikaddour et al., 2008: *Biochimica et Biophysica Acta* 1778: 2535-2543


## V- General Conclusion

## VI- Perspectives

# I- Introduction

## Pharmacology of Fluoroquinolones


- ✓ Synthetic origin compounds: Quinoline ring and Fluor atom at R<sub>6</sub>
- ✓ Bactericide activity
- ✓ Based on chemical structure and antibacterial activity:  
3 generations



- **1st generation (Quinolones)** ⇒ Treatment of urinary tract infections (1960-1970)
- **2<sup>nd</sup> generation** ⇒ Systematic use in the (1980-1990)
- **3<sup>rd</sup> generation** ⇒ Treatment of respiratory tract infections (from 1990-xxxx)

# I- Introduction


## Pharmacology of fluoroquinolones



✓ Bacterial targets are DNA gyrase and Topoisomerase IV.

# I- Introduction

## Mechanisms of resistance




### Resistance due to target enzymes mutation:

- mutations in topoisomerase IV (ParC or ParE)
- mutations in DNA gyrase (GyrA or GyrB)

- resistance due to a protective mechanism (ex. plasmid qnr)

### - Resistance due to altered access of drug to target enzymes:


- ✓ Difficulty to diffuse through the membrane
- ✓ Efflux system (efflux pumps in bacteria ex: AcrAB-TolC of *E.coli*)



ciprofloxacin

## I- Introduction

Previous studies on accumulation of CIP and MXF




moxifloxacin

Eukaryotic cells

J774 macrophages cells


+ MRP inhibitors



✓ MRP inhibitors had no effect on the accumulation of MXF

✓ MRP inhibitors increase the accumulation of CIP


- MRP inhibitors



✓ Intracellular accumulation


✓ Accumulation of MXF >>>CIP

# I-Introduction



To reach intracellular bacteria target, **CIP** and **MXF** interact with membrane lipids bilayer:

- ✓ where they can be recognized by the **efflux pumps proteins** in eukaryotic cells
- ✓ and/or the **porins** and **efflux pumps proteins** in prokaryotic cells



Investigation of interaction of FQs with model membranes at molecular level

## II- Aims of Thesis

---


Characterize the effect of two fluoroquinolones, **CIP** and **MXF**, on the physicochemical properties of the major phospholipids of both the eukaryotic and prokaryotic membranes:

- ✓ *Investigation of the interaction of two fluoroquinolones (**CIP** and **MXF**) with model lipid membranes.*
- ✓ *Investigation of the interaction of **CIP** with eukaryotic and prokaryotic model lipids membranes (DPPC vs DPPG).*




### III- Materials and methods

✓ Antibiotics: **CIP** and **MXF**




✓ Zwitterionic phospholipids  
(Eukaryotic cells: DOPC, DPPC)



✓ Anionic phospholipids  
(Prokaryotic cells: DPPG)


# III- Materials and methods

## Models of lipids membranes



### III- Materials and methods



#### i) Atomic Force Microscopy (AFM)



- ✓ Measure the forces resulting from different interactions between a tip, which is attached to a cantilever and the atoms of the sample surface.


# i) Atomic Force Microscopy

## How it's work?




- ✓ *Surface topography*
- ✓ *Lipid domain structure*

## ii) Langmuir-Blodgett technology (LB)




✓ Measure the surface pressure/area ( $\pi$ -A) of monomolecular layer upon compression

## ii) Pressure/area ( $\pi$ -A) isotherm curve for a phospholipid monolayer




Compression of lipids ( $\downarrow$  molecular area)  $\Rightarrow$   $\uparrow$  lateral pressure




- ✓ *Lipid molecular arrangement*
- ✓ *Lipid state transition*
- ✓ *Lipid packing*

### iii) Fourier Transform Infrared Spectroscopy (FTIR)



- ✓ IR beam is focused into the ATR crystal which is covered with lipid layer
- ✓ The light travels inside the plate by internal reflections from one surface of the plate to the other
- ✓ Absorption of the energy by the sample provides **ATR-FTIR spectra** and information about the **structure** of the system.

### iii) Fourier Transform Infrared Spectroscopy (FTIR)



✓ *Non polarized spectra for :*


- *state behavior* ( $\text{CH}_2$  asymmetric and symmetric stretching bands  $2800\text{-}3000 \text{ cm}^{-1}$ )
- *conformation* determination of lipids: ( $\text{CH}_2$  wagging bands ( $1400 \text{ cm}^{-1}$ ))

✓ *Polarized spectra for determination of lipids orientation:* Dichroism measurements of the  $\text{CH}_2$  wagging band ( $1400 \text{ cm}^{-1}$ )




## iv) Nuclear Magnetic Resonance spectroscopy (NMR)




### Chemical shift anisotropy $\Delta\sigma$



Bilayer



LUV liposome





$$\Delta\sigma = \sigma_{\parallel} - \sigma_{\perp}$$






$\sigma_{\parallel}$ : The low field shoulder  
 $\sigma_{\perp}$ : The high field peak

- ✓ *Mobility of phosphate heads of phospholipids*
- ✓ *Drug effect on the orientation of phospholipids head groups ( $^{31}\text{P}$  NMR).*

## v) Steady state anisotropy fluorescence



$$r = (I_{//} - I_{\perp}) / (I_{//} + 2 I_{\perp})$$



✓ *Binding parameters of drugs to lipids (stoichiometry, affinity)*

## IV- Results

*i) Investigation of the interaction of two fluoroquinolones (CIP and MXF) with model lipid membranes*

---

# Chapter I



# a) Effect of FQs on the membrane organization

## AFM Studies

(Collaboration with Pr Y. Defrene (UCL))


CIP

MXF



DPPC

DOPC



i) MXF induced in a more (57%) extent than CIP (27%), an erosion of the DPPC domains in the DOPC fluid phase



## b) FQs stability within a lipid monolayer / compressibility

### Langmuir studies

(Collaboration with Dr M. Deleu (FSAG, Gembloux))

CIP

MXF



ii) **MXF** induced a higher shift of the surface pressure-area isotherms of DOPC:DPPC:FQs monolayer towards the lower area per molecule as compared to **CIP**.



## c) ATR-FTIR Data analysis

*(Collaboration with Pr E.Goormaghtigh (SFMB, ULB))*



### ✓ Conformation analysis


⇒ Non polarized spectra of DPPC and DPPC:FQS with molar ratio of 1:1

### ✓ Orientation analysis

⇒ Dichroic spectra ( $A_{//} - A_{\perp}$ ) of DPPC and DPPC: FQs with molar ratio of 1:1

## C i) Conformation analysis

Non polarized spectra of drug, DPPC and DPPC:FQS with molar ratio of 1:1





- ✓ The drug spectrum appeared in the DPPC: drug mixture spectrum, notably at **1630  $\text{cm}^{-1}$** .
- ✓ In DPPC: drug spectra, the DPPC  $\nu(\text{C}=\text{O})$  band at **1736  $\text{cm}^{-1}$**  was modified in terms of frequency and shape

⇒ a modification of the interfacial lipid carbonyl groups

## C i) Conformation analysis

Analysis of the lipid C-H wagging ( $\nu_w(\text{CH}_2)$ )  $\Rightarrow$  Information on the proportion of the chains in the all-trans conformation





- ✓ Area evolution of DPPC peak at **1206-1193 cm<sup>-1</sup>** as function of increasing amounts of FQs : **↓ 60% for CIP**, **↓ 72% for MXF**.
- $\Rightarrow$  The all-trans configuration of the alkyl chain of DPPC **decreased** more in the presence of **MXF**.



## C ii) Orientation analysis

Dichroic spectra ( $A_{//} - A_{\perp}$ ) of DPPC and DPPC:FQs

with molar ratio of 1:1





✓ The dichroic spectra of DPPC:FQs mixture displayed strong dichroism for bands assigned to the drug (at 1630 and 1465  $\text{cm}^{-1}$ )

⇒ a well-organized, well-defined orientation of the drug in the DPPC bilayer.

## C ii) Orientation analysis

Analysis of the lipid C-H wagging ( $\nu_w(\text{CH}_2)$ ) band  $\Rightarrow$  Estimation of the orientation of the lipid acyl chain




✓ Area evolution of the wagging band  $\nu_w(\text{CH}_2)$  of DPPC as a function of lipid:Drug molar ratio, indicated :

-  $\downarrow$  60% of the area for CIP,  $\downarrow$  30% for MXF.

- The tilt between the acyl chain of DPPC and a normal at the germanium surface was ( $27^\circ$ ) in the presence of CIP and remained unchanged ( $20^\circ$ ) in the presence of MXF

$\Rightarrow$  MXF induced less disorder than CIP

# Summary 1



- ✓ **MXF** induced in a more extent than **CIP** an erosion of the DPPC domains in the DOPC fluid phase.
- ✓ **MXF** induced a higher shift of the surface pressure-area isotherms of DOPC: DPPC: FQs monolayer towards the lower area per molecule as compared to **CIP**.
- ✓ **MXF** had a higher tendency to decrease the number of all-trans conformation, as compared to **CIP**.
- ✓ **CIP** induced a disorder and modifies the orientation of the acyl chain.

*ii) Investigation of the interaction of CIP with eukaryotic and prokaryotic model lipids membranes (DPPC vs DPPG)*

---

# Chapter II

## Phospholipids composition (%) of bacteria membrane and human cells membrane

Lipid	Eukaryotic cells		Prokaryotic cells		
	Human alveolar macrophages	Human Erythrocyte membrane	<i>Pseudomonas aeruginosa</i>	<i>Staphylococcus aureus</i>	<i>Staphylococcus pneumoniae</i>
PE	20.6	6.2	60	-	-
PC	31	24.2	-	-	-
PS	20.7	2.6	Traces		
PG+CL			21+11	58+42	50+50
PI+PA			-	-	-
SM	6.6	18.9	-	-	-
Chol	7.9	48.1			
Others	13.2				

- ✓ The bacterial membranes are composed largely of anionic lipids (PG).
- ✓ The eukaryotic cell membranes are rich with zwitterionic lipids.

## 1) Binding of CIP to Lipids


### a) Size of LUVs in the presence of CIP by quasi-elastic light scattering

Lipid-Drug Molar ratio	Average size (nm) LUV	
	DPPC	DPPG
1:0	101±1	124±1
1:0.2	100±1	155±2
1:0.5	98±1	195±2
1:1	105±1	256±5

⇒ CIP increased the size of DPPG liposomes

a ) Binding of CIP to Lipids by steady state anisotropy titration

[CIP] = 5  $\mu$ M



$$r = (I_{//} - I_{\perp}) / (I_{//} + 2 I_{\perp})$$

$$K_{app} = (8.6 \pm 0.5) 10^5 \text{ M}^{-1}$$

Thesis-H.Bensikaddour

### a) Binding parameters of CIP with Lipids vesicles

LUV liposomes Composition	Zeta potential (mV)	$K_{app}(10^5 M^{-1})$
DPPG	$-(66 \pm 4)$ (83 $\pm$ 12 %)	$8.6 \pm 0.5$
DPPC	$-(5 \pm 1)$ (96 $\pm$ 5 %)	$2.5 \pm 0.1$
DOPC:DPPG (1:1, M:M)	$-(34 \pm 4)$ (100%)	$3.2 \pm 0.9$
DOPC:DPPC (1:1, M:M)	$-(6 \pm 1)$ (100%)	$1.1 \pm 0.2$


⇒ **CIP** has more affinity for negative charged liposomes  
(DPPG Vs DPPC)



## 2) CIP effect on the membrane mobility

(Collaboration with Pr K. Snoussi (CHIM, UCL))

### i) DPPG




$\Delta\sigma=25.5\pm0.5$  ppm


$\Delta\sigma=34.0\pm1.0$  ppm

$\Rightarrow$  The difference of  $\Delta\sigma$  of DPPG:CIP and DPPG is **9 ppm**

## 2) CIP effect on the membrane mobility ii) DPPC



$$\Delta\sigma = 41.5 \pm 0.5 \text{ ppm}$$




$$\Delta\sigma = 46.6 \pm 0.1 \text{ ppm}$$

⇒ The difference of  $\Delta\sigma$  of DPPC:CIP and DPPC is **5 ppm**


### 3) CIP effect on the thermotropic behavior of lipids

Melting temperature of lipid by ATR-FTIR



#### CH<sub>2</sub> Stretching vibrations


Evolution of stretching vibration bands of CH<sub>2</sub> of DPPG as function of temperature in the presence of CIP in Tris 10mM buffer, pH 7,4




### 3) CIP effect on thermotropic curve of DPPG and DPPC

#### CH<sub>2</sub> asymmetric stretching band

Melting temperature of DPPG  
and DPPG:CIP (1:1)



Melting temperature of DPPC  
and DPPC:CIP (1:1)




$T_m(\text{DPPG}) = 40 \text{ C}^\circ$ ,  $T_m(\text{DPPC}) = 42 \text{ C}^\circ$

- ✓ CIP did not affect dramatically the DPPC melting curve
- ✓ CIP : ↓ order of acyl chain of DPPG <  $T_m$   
↑ order of acyl chain of DPPG >  $T_m$

## 4) Assembly of CIP with phospholipids by molecular modeling


*(Collaboration with Dr L. Lins (CBMN, Gembloux))*

**DPPC:CIP (1:1, M:M)**



$E = - 44.4 \text{ Kcal/mol}$


**DPPG:CIP (1:1, M:M)**



$E = - 53.4 \text{ Kcal/mol}$

**=> The interaction of DPPG:CIP is more stable than DPPC:CIP**

## Summary 2




The results showed that ciprofloxacin:

- ✓ had more affinity to the negatively charged lipid
- ✓ reduced more the mobility of DPPG than DPPC
- ✓ had no dramatic effect on the melting curve of DPPC
- ✓ decreased the order of acyl chain of DPPG at pre-transition temperature and increased the order at post-transition temperature




## VI- Perspectives

- ✓ Relationship between the membrane composition and the permeability of these compounds (**CIP** and **MXF**) by the Parallel Artificial Membrane Permeability Assay
- ✓ Molecular modeling of MRP4 protein in the lipid bilayer in the absence and the presence of either **CIP** or **MXF**
- ✓ Are there correlation between lipid composition and efflux pumps protein expression?



Determination of the lipids composition in J774 cells wild type and those overexpressed MRP4 protein (resistant to **CIP**)




An alteration in the sphingolipids composition was observed: an **increased** level of **GluCer**, and a **decreased** content in **Cer** and in **SM**

(Bensikaddour et al., Unpublished data)




## VI- Perspectives

- ✓ Application to others fluoroquinolones (role of lipophilicity, the basic function (piperazine))



Grepafloxacin (Log P=2.48)



nadifloxacin

# Acknowledgements

- ✓ Pr M-P. Mingeot-Leclercq
- ✓ Pr P. Tulkens, Pr F. Van Bambeke
- ✓ Pr E. Goormaghtigh (SFMB, ULB, Brussels)
- ✓ Pr K. Snoussi (CHIM,UCL, Louvain-la-Neuve)
- ✓ Dr L. Lins (CBMN, Gembloux)
- ✓ Pr M. Fillet (ULg, Liège)
- ✓ FACM'S members
- ✓ My Family



**Thanks' for your attention !**